The Effects of Probiotics, Lactobacillus GG, in the Treatment of Abdominal Pain in Children With Functional Abdominal Pain Disorders

Phase 4

Recruiting

• Conditions: Functional Abdominal Pain Syndrome
• Interventions: Drug: LGG; Drug: Placebo

• Registration Number: NCT06310733
• Lead Sponsor: Prince of Songkla University

Brief Summary

Recurrent or chronic abdominal pain is one of the common gastrointestinal problems in children. While most children do not have organic origins (so called functional abdominal pain disorders; FAPDs), the symptoms can nevertheless be severe enough to impair the patient's quality of life, growth, and development. To help rule out organic disorders and diagnose this condition, some individuals underwent multiple invasive and costly studies.

Generally, the diagnosis of FAPDs is based on clinical symptoms and criteria, it can be divided into irritable bowel syndrome (IBS), abdominal migraine, functional abdominal pain (FAP) and functional dyspepsia (FD). Approximately 14% of children globally, between the ages of 4 and 18, experience functional abdominal pain issues8. In Thailand, the prevalence of FAPDs among adolescents (mean age of 16 years) was 5.3%, functional dyspepsia and irritable bowel syndrome were found to be the most prevalent subtypes.

The pathogenesis of FAPDs is believed to result from disruptions in the microbiota-gut-brain axis, which may happen early in life or throughout. Hence, several studies, specifically in western countries, reported the role of probiotics, specifically Lactobacillus rhamnosus GG (LGG), in modulating abdominal symptoms in children with FAPDs.

It is widely known that the diversity of gut microbiota depends on multiple factors including ethnicity, mode of delivery, dietary and environmental factors. However, the studies on the use of probiotics in pediatric patients with FAPDs have been mainly conducted in western countries. Since there are limited studies on the effectiveness of probiotics in Asian children with FAPDs, the investigators aim to evaluate the effects of probiotics, LGG, in the treatment of children who suffered from FAPDs.

The secondary objectives are to measure daily pain score in children with and without FAPDs, to evaluate and compare the diversity of fecal microbiota in children with FAPDs and those without FAPDs, and to compare the diversity of fecal microbiota between children with FAPDs who took probiotics and those who did not.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-02-26
• Status Verified: 2024-03
• Study First Submitted QC: 2024-03-06
• Last Update Submitted: 2024-03-14
• Study First Posted: 2024-03-15
• Last Update Posted: 2024-03-18
• Study Start: 2024-03-21
• Primary Completion: 2025-12-31
• Study Completion: 2026-02-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 54

Inclusion Criteria

• Children, aged 6-15 years old, with a diagnosis of IBS or FAP, according to the Rome IV diagnostic criteria. The diagnosis of IBS or FAP was based on a clinical interview performed by pediatric gastroenterologist.

For healthy controls: non-obese children, aged 6-15 years old, without any gastrointestinal symptoms at the time of recruitment.

Read More

Exclusion Criteria

• Children who

  1. had any chronic diseases, including neurobehavioral disorders
  2. received treatment with antibiotics/probiotics in the previous 2 months
  3. received medication that affects gastrointestinal motility in the previous 1 week
  4. had a pain history suggestive of functional dyspepsia/aerophagia/abdominal migraine/functional constipation
  5. exhibited growth failure
  6. had gastrointestinal obstructions/stricture
  7. displayed alarming signs of organic condition
  8. had previous abdominal surgery
  9. had abnormal baseline test results as part of their standard work-up (e.g. complete blood counts; erythrocyte sedimentation rate; liver-pancreas-kidney function tests; stool examination for occult blood, ova, and parasites; fecal calprotectin; urinalysis; abdominal ultrasound; 13C-urea breath test; gastric emptying study, if any)
  10. had family history of peptic ulcer disease or inflammatory bowel disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
LGG (ATCC 53103)	LGG	A suspension of freeze-dried LGG ATCC53103 in excipients in an aqueous solution supplied in a 10-mL dark bottle with a delivery cap.
Placebo	Placebo	An identical aqueous solution in appearance and taste but without LGG.

Primary Outcome Measures

Name	Time	Method
The response rate of 4 week-probiotics (LGG) on the severity of abdominal pain (number of episodes or the intensity of pain), compared to the conventional treatment, in children who suffered from FAPDs	12 weeks	Daily food and symptom record

Secondary Outcome Measures

Name	Time	Method
To measure daily pain score in children with and without FAPDs	12 weeks	Daily food and symptom record
To compare the diversity of fecal microbiota in children with FAPDs who took probiotics and those who did not	4 weeks	stool samples for rDNA sequencing before and after 4 weeks of treatment.

Trial Locations

Locations (1)

Atchariya Chanpong; 🇹🇭 Songkhla, Thailand